Central serous chorioretinopathy: Towards an evidence-based treatment guideline

Thomas J. van Rijssen, Elon H.C. van Dijk, Suzanne Yzer, Kyoko Ohno-Matsui, Jan E.E. Keunen, Reinier O. Schlingemann, Sobha Sivaprasad, Giuseppe Querques, Susan M. Downes, Sascha Fauser, Carel B. Hoyng, Felice Cardillo Piccolino, Jay K. Chhablani, Timothy Y.Y. Lai, Andrew J. Lotery, Michael Larsen, Frank G. Holz, K. Bailey Freund, Lawrence A. Yannuzzi, Camiel J.F. Boon*

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

323 Citations (Scopus)
320 Downloads (Pure)

Abstract

Central serous chorioretinopathy (CSC) is a common cause of central vision loss, primarily affecting men 20–60 years of age. To date, no consensus has been reached regarding the classification of CSC, and a wide variety of interventions have been proposed, reflecting the controversy associated with treating this disease. The recent publication of appropriately powered randomised controlled trials such as the PLACE trial, as well as large retrospective, non-randomised treatment studies regarding the treatment of CSC suggest the feasibility of a more evidence-based approach when considering treatment options. The aim of this review is to provide a comprehensive overview of the current rationale and evidence with respect to the variety of interventions available for treating CSC, including pharmacology, laser treatment, and photodynamic therapy. In addition, we describe the complexity of CSC, the challenges associated with treating CSC, and currently ongoing studies. Many treatment strategies such as photodynamic therapy using verteporfin, oral mineralocorticoid antagonists, and micropulse laser treatment have been reported as being effective. Currently, however, the available evidence suggests that half-dose (or half-fluence) photodynamic therapy should be the treatment of choice in chronic CSC, whereas observation may be the preferred approach in acute CSC. Nevertheless, exceptions can be considered based upon patient-specific characteristics.

Original languageEnglish
Article number100770
JournalProgress in Retinal and Eye Research
Volume73
Number of pages40
ISSN1350-9462
DOIs
Publication statusPublished - Nov 2019

Keywords

  • Central serous chorioretinopathy
  • Guideline
  • Micropulse laser
  • Mineralocorticoid antagonist
  • Photodynamic therapy
  • Retina
  • Treatment

Cite this